T1 mapping and amyloid cardiomyopathy: How much better can it get?

European Heart Journal

Volumn 36, Issue 4, 2015, Pages 203-205

  Karamitsos, Theodoros D ^a,b   Neubauer, Stefan ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; GADOLINIUM;

AORTA STENOSIS; CARDIAC MAPPING SYSTEM; CARDIOVASCULAR MAGNETIC RESONANCE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED CLINICAL TRIAL (TOPIC); EXTRACELLULAR SPACE; HEART AMYLOIDOSIS; HEART LEFT VENTRICLE; HEART MUSCLE BIOPSY; HUMAN; HUMAN TISSUE; IMAGE ENHANCEMENT; LIGHT CHAIN; MEDICAL DECISION MAKING; NEPHROGENIC SYSTEMIC FIBROSIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TISSUE CHARACTERIZATION; AMYLOIDOSIS; CARDIOMYOPATHY; FEMALE; MALE; MORTALITY;

AMYLOIDOSIS; CARDIOMYOPATHIES; FEMALE; HUMANS; MALE;

EID: 84926200443     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu442     Document Type: Review

References (15)

1. Banypersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar AD. Updates in cardiac amyloidosis: a review. J Am Heart Assoc 2012; 1: e000364.
2. Vogelsberg H, Mahrholdt H, Deluigi CC, Yilmaz A, Kispert EM, Greulich S, Klingel K, Kandolf R, Sechtem U. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol 2008; 51: 1022-1030.
3. Ruberg FL, Appelbaum E, Davidoff R, Ozonoff A, Kissinger KV, Harrigan C, Skinner M, Manning WJ. Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis. Am J Cardiol 2009; 103: 544-549.
4. Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, Sheppard MN, Poole-Wilson PA, Hawkins PN, Pennell DJ. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005; 111: 186-193.
5. Moon JC, Messroghli DR, Kellman P, Piechnik SK, Robson MD, Ugander M, Gatehouse PD, Arai AE, Friedrich MG, Neubauer S, Schulz-Menger J, Schelbert EB, Society for Cardiovascular Magnetic Resonance Imaging, Cardiovascular Magnetic Resonance Working Group of the European Society of Cardiolog.Myocardial T1 mapping and extracellular volumequantification: a Society for CardiovascularMagnetic Resonance (SCMR) and CMRWorking Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson 2013; 15: 92.
6. Ferreira VM, Piechnik SK, Robson MD, Neubauer S, Karamitsos TD. Myocardial tissue characterization by magnetic resonance imaging: novel applications of T1 and T2 mapping. J Thorac Imaging 2014; 29: 147-154.
7. Karamitsos TD, Piechnik SK, Banypersad SM, Fontana M, Ntusi NB, Ferreira VM, Whelan CJ, Myerson SG, Robson MD, Hawkins PN, Neubauer S, Moon JC. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging 2013; 6: 488-497.
8. Banypersad SM, Sado DM, Flett AS, Gibbs SD, Pinney JH, Maestrini V, Cox AT, Fontana M, Whelan CJ, Wechalekar AD, Hawkins PN, Moon JC. Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging 2013; 6: 34-39.
9. Bandula S, Banypersad SM, Sado D, Flett AS, Punwani S, Taylor SA, Hawkins PN, Moon JC. Measurement of tissue interstitial volume in healthy patients and those with amyloidosis with equilibrium contrast-enhanced MR imaging. Radiology 2013; 268: 858-864.
10. Banypersad SM, Fontana M, Maestrini V, Sado D, Captur G, Petrie A, Whelan CJ, Herrey AS, Gillmore JD, Lachmann HJ, Wechalekar AD, Hawkins PN, Moon JC. T1 mapping and survival in systemic AL amyloidosis. Eur Heart J 2015; 36: 244-251.
11. Maceira AM, Prasad SK, Hawkins PN, Roughton M, Pennell DJ. Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson 2008; 10: 54.
12. Austin BA, Tang WH, Rodriguez ER, Tan C, Flamm SD, Taylor DO, Starling RC, Desai MY. Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. JACC Cardiovasc Imaging 2009; 2: 1369-1377.
13. White JA, Kim HW, Shah D, Fine N, Kim KY, Wendell DC, Al-Jaroudi W, Parker M, Patel M, Gwadry-Sridhar F, Judd RM, Kim RJ. CMRimaging with rapid visualT1 assessment predicts mortality in patients suspected of cardiac amyloidosis. JACC Cardiovasc Imaging 2014; 7: 143-156.
14. Ferreira VM, Piechnik SK, DallArmellina E, Karamitsos TD, Francis JM, Ntusi N, Holloway C, Choudhury RP, Kardos A, Robson MD, Friedrich MG, Neubauer S. Native T1-mapping detects the location, extent and patterns of acute myocarditis without the need for gadolinium contrast agents. J Cardiovasc Magn Reson 2014; 16: 36.
15. Gillmore JD, Hawkins PN. Pathophysiology and treatment of systemic amyloidosis. Nat Rev Nephrol 2013; 9: 574-586.